<qa>  What is the PASI score for therapeutic response?Patients with moderate to severe psoriasis who have received treatment with adalimumab loading dose of 80 mg and thereafter 40 mg s.c. biweekly for at least 6 weeks without a PASI reduction of 75 or greater qualify for the study. Adalimumab is continued and UVB-311nm phototherapy is added at 6 weeks or thereafter one a randomized body half left or right; head exempt 3 x per week until complete response defined as reduction in PASI to 3 for a maximum of another 6 weeks until week 12. PASI score, visual analogue score VAS patient score for therapeutic response, and VAS patient score for severity of skin lesions is assessed weekly; and at follow-up visits at month 3, 6, and 12. Paired Wilcoxon testing for differences in PASI and patient VAS scores is done; Fischer exact test is applied to determine differences in complete remission, PASI reduction 90, 75 andor 50 between body sites. 